Cited by 173Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

Open access

Bahne, Emilie, Sun, Emily W. L., Young, Richard L., Hansen, Morten, Sonne, David P., Hansen, Jakob S., Rohde, Ulrich, Liou, Alice P., Jackson, Margaret L., de Fontgalland, Dayan, Rabbitt, Philippa, Hollington, Paul, Sposato, Luigi, Due, Steven, Wattchow, David A., Rehfeld, Jens F., Holst, Jens J., Keating, Damien J., Vilsbøll, Tina, Knop, Filip K.·2018·JCI Insight

DOI 10.1172/jci.insight.93936PMC PMC6328020

Open this paper in CoChat — free account

Abstract

BACKGROUND: Metformin reduces plasma glucose and has been shown to increase glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 release, and whether some of the glucose-lowering effect of metformin occurs due to GLP-1 release, is unknown. The current study investigated metformin-induced GLP-1 secretion and its contribution to the overall glucose-lowering effect of metformin and underlying mechanisms in patients with type 2 diabetes. METHODS: Twelve patients with type 2 diabetes were included in this placebo-controlled, double-blinded study. On 4 separate days, the patients received metformin (1,500 mg) or placebo suspended in a liquid meal, with subsequent i.v. infusion of the GLP-1 receptor antagonist exendin9-39 (Ex9-39) or saline. During 240 minutes, blood was sampled. The direct effect of metformin on GLP-1 secretion was tested ex vivo in human ileal and colonic tissue with and without dorsomorphin-induced inhibiting of the AMPK activity. RESULTS: Metformin increased postprandial GLP-1 secretion compared with placebo (P = 0.014), and the postprandial glucose excursions were significantly smaller after metformin + saline compared with metformin + Ex9-39 (P = 0.004). Ex vivo metformin acutely increased GLP-1 secretion (colonic tissue, P < 0.01; ileal tissue, P < 0.05), but the effect was abolished by inhibition of AMPK activity. CONCLUSIONS: Metformin has a direct and AMPK-dependent effect on GLP-1-secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin's glucose-lowering effect and mode of action. TRIAL REGISTRATION: NCT02050074 (https://clinicaltrials.gov/ct2/show/NCT02050074). FUNDING: This study received grants from the A.P. Møller Foundation, the Novo Nordisk Foundation, the Danish Medical Association research grant, the Australian Research Council, the National Health and Medical Research Council, and Pfizer Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci.insight.93936

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,393
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Identification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993

Show all 72 references

Research works printed but not linked: 1

Jorsal, 2014, Altered enteroendocrine expression of glucagon and somatostatin in the gut of patients with type 2 diabetes compared with healthy matched controls, Diabetologia, 57

Sorted by citations

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release
Martin, A. M., Sun, E. W. L., Rogers, G. B., & Keating, D. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00428 · Cited by 402
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam-Galvez, K. J., Burnett, C. E., Venida, A. C., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 320
A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
The ever-changing roles of serotonin
Jones, L. A., Sun, E. W. L., Martin, A. M., & Keating, D. J. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105776 · Cited by 265
Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes
Milardi, D., Gazit, E., Radford, S. E., Xu, Y., Gallardo, R. U., Caflisch, A., Westermark, G. T., Westermark, P., Rosa, C. L., & Ramamoorthy, A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00981 · Cited by 199
Air−Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions
Baldassi, D., Gabold, B., & Merkel, O. M. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000111 · Cited by 175
Metformin and Aging: A Review
Glossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149
Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
Xie, C., Huang, W., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2021) · Nutrients · doi:10.3390/nu13041104 · Cited by 124
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 143
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 116
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105
AMPK and the Endocrine Control of Metabolism
Townsend, L. K., & Steinberg, G. R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad012 · Cited by 114
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Yin, R., Xu, Y., Wang, X., Yang, L., & Zhao, D. (2022) · Molecules · doi:10.3390/molecules27103055 · Cited by 98
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Bhansali, S., Bhansali, A. K., Dutta, P. R., Walia, R., & Dhawan, V. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14834 · Cited by 82
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 86
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 73
Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials
Benedetti, R., Benincasa, G., Glass, K., Chianese, U., Vietri, M. T., Congi, R., Altucci, L., & Claudio Napoli, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106039 · Cited by 75
Examining the clinical relevance of metformin as an antioxidant intervention
Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Adamska, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1330797 · Cited by 77
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 79
The Mechanism of Action of Biguanides: New Answers to a Complex Question
Magno, L. D., Pastena, F. D., Bordone, R., Coni, S., & Canettieri, G. (2022) · Cancers · doi:10.3390/cancers14133220 · Cited by 81
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 75
Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes
Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes · doi:10.2337/db23-0356 · Cited by 74
Understanding the action mechanisms of metformin in the gastrointestinal tract
Cheng, M., Ren, L., Jia, X., Wang, J., & Cong, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347047 · Cited by 78
Increased hepatic gluconeogenesis and type 2 diabetes mellitus
Barroso, E., Jurado-Aguilar, J., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.006 · Cited by 75
The role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 63
The composition of the gut microbiota following early-life antibiotic exposure affects host health and longevity in later life
Lynn, M. A., Eden, G. L., Ryan, F. J., Bensalem, J., Wang, X., Blake, S. J., Choo, J. M., Tee, Y. C., Sribnaia, A., James, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109564 · Cited by 62
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Pharmacology of metformin – An update
Glossmann, H. H., & Lutz, O. M. D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172782 · Cited by 62
Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection
Michlmayr, D., Kim, E., Rahman, A. H., Raghunathan, R. R., Kim‐Schulze, S., Che, Y., Kalaycı, S., Gumus, Z. H., Kuan, G., Balmaseda, Á., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107569 · Cited by 51
Effects of different doses of exercise and diet-induced weight loss on beta-cell function in type 2 diabetes (DOSE-EX): a randomized clinical trial
Legaard, G. E., Lyngbæk, M. P. P., Almdal, T., Karstoft, K., Bennetsen, S. L., Feineis, C. S., Nielsen, N. S., Durrer, C. G., Liebetrau, B., Nystrup, U., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00799-7 · Cited by 55
Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus
Hou, Y., Zhai, X., Wang, X., Wu, Y., Wang, H., Qin, Y., Han, J., & Meng, Y. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01207-6 · Cited by 59
Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence
Vessoni, A. T., Filippi‐Chiela, E. C., Lenz, G., & Batista, L. F. Z. (2019) · Oncogene · doi:10.1038/s41388-019-1128-4 · Cited by 59
Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy
Liu, Y., Afzal, J. M., Vakrou, S., Greenland, G. V., Talbot, C. C., Hebl, V. B., Guan, Y., Karmali, R., Tardiff, J. C., Leinwand, L. A., et al. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00170 · Cited by 48
Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 51
Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa074 · Cited by 37
Mitochondrial AIF loss causes metabolic reprogramming, caspase-independent cell death blockade, embryonic lethality, and perinatal hydrocephalus
Delavallée, L., Mathiah, N., Cabon, L., Mazeraud, A., Brunelle-Navas, M.-N., Lerner, L. K., Tannoury, M., Prola, A., Moreno‐Loshuertos, R., Baritaud, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101027 · Cited by 35
Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats
Dik, B., Coşkun, D., Bahçıvan, E., & Üney, K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-38 · Cited by 32
Metformin: From diabetes to cancer to prolongation of life
Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107367 · Cited by 38
The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment
Mu, W., Liang, G., Feng, Y., Jiang, Y., & Qu, F. (2022) · Pharmaceuticals · doi:10.3390/ph15101274 · Cited by 30
Myeloid-Derived Growth Factor Promotes Intestinal Glucagon-Like Peptide-1 Production in Male Mice With Type 2 Diabetes
Wang, L., Li, Y., Guo, B., Zhang, J., Zhu, B., Li, H., Ding, Y., Meng, B., Zhao, H., Xiang, L., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa003 · Cited by 31
Labyrinthopeptin A1 inhibits dengue and Zika virus infection by interfering with the viral phospholipid membrane
Oeyen, M., Meyen, E., Noppen, S., Claes, S., Doijen, J., Vermeire, K., Süßmuth, R. D., & Schols, D. (2021) · Virology · doi:10.1016/j.virol.2021.07.003 · Cited by 29
Hyperglycemia induces NF‐κB activation and MCP‐1 expression via downregulating GLP‐1R expression in rat mesangial cells: inhibition by metformin
Kang, Z., Zeng, J., Zhang, T., Lin, S., Gao, J., Jiang, C., Fan, R., & Yin, D. (2019) · Cell Biology International · doi:10.1002/cbin.11184 · Cited by 29
Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 28
The Hormetic Effect of Metformin: “Less Is More”?
Panfoli, I., Puddu, A., Bertola, N., Ravera, S., & Maggi, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126297 · Cited by 29
Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice
Bravard, A., Gérard, C., Defois, C., Benoit, B., Makki, K., Meugnier, E., Rainteau, D. P., Rieusset, J., Godet, M., & Vidal, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-95117-0 · Cited by 28
Metformin-mediated epigenetic modifications in diabetes and associated conditions: Biological and clinical relevance
Giordo, R., Posadino, A. M., Mangoni, A. A., & Pintus, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115732 · Cited by 28
From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
Poznyak, A. V., Litvinova, L. S., Poggio, P., Moschetta, D., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179738 · Cited by 27
A Single Dose of Oral Metformin Reduces the Post-Prandial Glucose Response Through a Transient Modulation of Apical Sodium-Glucose Co-Transporter
Zubiaga, L., Briand, O., Auger, F., Touche, V., Hübert, T., Thévenet, J., Marciniak, C., Quenon, A., Bonner, C., Peschard, S., et al. (2019) · iScience · doi:10.1016/j.isci.2023.106057 · Cited by 28
Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question
Tocci, V., Mirabelli, M., Salatino, A., Sicilia, L., Giuliano, S., Brunetti, F. S., CHIEFARI, E. D., Sarro, G. D., FOTI, D. P., & Brunetti, A. (2023) · Pharmaceuticals · doi:10.3390/ph16091318 · Cited by 31
Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 22
Metformin triggers PYY secretion in human gut mucosa
Sun, E. W. L., Martin, A. M., Wattchow, D. A., DeFontgalland, D., Rabbitt, P., Hollington, P., Young, R. L., & Keating, D. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02460 · Cited by 23
A Planar Culture Model of Human Absorptive Enterocytes Reveals Metformin Increases Fatty Acid Oxidation and Export
Gomez-Martinez, I., Bliton, R. J., Breau, K. A., Czerwinski, M. J., Williamson, I., Wen, J., Rawls, J. F., & Magness, S. T. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.04.009 · Cited by 22
Examining the predictive accuracy of metabolomics for small-for-gestational-age babies: a systematic review
Leite, D. F. B., Morillon, A.-C., Junior, E. F. D. M., Souza, R. T., McCarthy, F. P., Khashan, A. S., Baker, P. N., Kenny, L. C., & Cecatti, J. G. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031238 · Cited by 21
Management of Diabetes in Patients Undergoing Bariatric Surgery
Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 24
Alterations in GLP-1 and PYY release with aging and body mass in the human gut
Jones, L. A., Sun, E. W. L., Lumsden, A. L., Thorpe, D. W., Peterson, R. A., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112072 · Cited by 23
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery
Sari, C., Seip, R. L., & Umashanker, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.588016 · Cited by 20
Stimulatory effect of imeglimin on incretin secretion
Yingyue, Q., Sugawara, K., Takahashi, H., Yokoi, N., Ohbayashi, K., Iwasaki, Y., Seino, S., & Ogawa, W. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14001 · Cited by 22
Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 22
Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
Lok, K.-H., Wareham, N. J., Nair, R. S., How, C. W., & Chuah, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106237 · Cited by 19
Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study
Xie, C., Iroga, P. E., Bound, M. J., Grivell, J., Huang, W., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2024) · Diabetologia · doi:10.1007/s00125-024-06131-6 · Cited by 23
Povidone iodine treatment is deleterious to human ocular surface conjunctival cells in culture
Swift, W., Bair, J. A., Chen, W., Li, M., Lie, S., Li, D., Yang, M., Shatos, M. A., Hodges, R. R., Kolko, M., et al. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000545 · Cited by 18
Metformin: A Promising Antidiabetic Medication for Cancer Treatment
Mu, W., Jiang, Y., Liang, G., Feng, Y., & Qu, F. (2022) · Current Drug Targets · doi:10.2174/1389450124666221104094918 · Cited by 18
Treatment of type 2 diabetes mellitus in the elderly – Special considerations
Gadó, K., Tabák, Á. G., Vingender, I., Domján, G., & Dörnyei, G. (2024) · Physiology International · doi:10.1556/2060.2024.00317 · Cited by 24
Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer
Bora, V. R., & Patel, B. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119329 · Cited by 18
Metformin action in the gut―insight provided by [18F]FDG PET imaging
Tsuchida, H., Morita, Y., Nogami, M., & Ogawa, W. (2021) · Diabetology International · doi:10.1007/s13340-021-00545-y · Cited by 16
Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies
Watkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 20
Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control
Sebo, Z. L., Chakrabarty, R. P., Grant, R. A., D’Alessandro, K. B., Koss, A., Blum, J. L. E., Davidson, S. M., Reczek, C. R., & Chandel, N. S. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01530-y · Cited by 21
Is metformin a geroprotector? A peek into the current clinical and experimental data
Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16
Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations
Sarnobat, D., Moffett, R. C., Flatt, P. R., & Tarasov, A. I. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01620-6 · Cited by 16
Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
Borg, M. J., Xie, C., Rayner, C. K., Horowitz, M., Jones, K. L., & Wu, T. (2021) · Nutrients · doi:10.3390/nu13082826 · Cited by 15
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes
Cravalho, C. K. L., Meyers, A. G., Mabundo, L. S., Courville, A. B., Yang, S. B., Cai, H., Dai, Y., Walter, M. F., Walter, P. J., Sharma, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05236-y · Cited by 17
Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model
Yao, Y., Li, X., Yang, X., Mou, H., & Wei, L. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102108 · Cited by 14
Striking a gut–liver balance for the antidiabetic effects of metformin
Barroso, E., Montori-Grau, M., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.004 · Cited by 14
Deep-learning on-chip light-sheet microscopy enabling video-rate volumetric imaging of dynamic biological specimens
Chen, X., Ping, J., Sun, Y., Yi, C., Liu, S., Gong, Z., & Fei, P. (2021) · Lab on a Chip · doi:10.1039/d1lc00475a · Cited by 14
Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial
Cesar, T. B., de Oliveira, M. R. M., Sandrim, V. C., Mendes, A., Bruder, R., de Oliveira, R. A. A., Sivieri, K., & Milenković, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1639901 · Cited by 16
Metformin Effects on SHIP2, AMPKs and Gut Microbiota: Recent Updates on Pharmacology
Shivaprakash, P., Beeraka, N. M., Madhunapantula, S. V., Nikolenko, V. N., & Basalingappa, K. M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673289342240213040144 · Cited by 14
Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial
Usui, R., Hamamoto, Y., Imura, M., Omori, Y., Yamazaki, Y., Kuwata, H., Tatsuoka, H., Shimomura, K., Murotani, K., Yamada, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16086 · Cited by 13
The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity
Pillai, A. A., Melo, L., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000832 · Cited by 17
Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
Borg, M. J., Rayner, C. K., Jones, K. L., Horowitz, M., Xie, C., & Wu, T. (2020) · Pharmaceuticals · doi:10.3390/ph13110410 · Cited by 15
CD14+monocytes are the main leucocytic sources of CXCL10 in response toPlasmodium falciparum
Ioannidis, L. J., Eriksson, E. M., & Hansen, D. S. (2019) · Parasitology · doi:10.1017/s0031182019001744 · Cited by 13
Chemosensing in enteroendocrine cells: mechanisms and therapeutic opportunities
Yang, M. H., Reimann, F. M., & Gribble, F. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000614 · Cited by 13
Evidence for Glucagon Secretion and Function Within the Human Gut
Sun, E. W. L., Martin, A. M., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., Colella, A. D., Chataway, T., Albrechtsen, N. J. W., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab022 · Cited by 13
Metformin increases the uptake of glucose into the gut from the circulation in high-fat diet-fed male mice, which is enhanced by a reduction in whole-body Slc2a2 expression
Morrice, N., Vainio, S., Mikkola, K., van Aalten, L., Gallagher, J. R., Ashford, M. L. J., McNeilly, A. D., McCrimmon, R. J., Grosfeld, A., Serradas, P., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101807 · Cited by 12
Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions
Jones, M., Ionescu, C. M., Walker, D., Wagle, S. R., Kovačević, B., Chester, J., Foster, T., Johnston, E., Kuthubutheen, J., Brown, D. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020836 · Cited by 13
Cellular mechanism of diabetes remission by bariatric surgery
Ye, J., Hu, Y.-X., Wang, C., Lian, H., & Dong, Z. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.07.001 · Cited by 11
Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes
Chu, N. H. S., Ling, J., Poon, E. W. M., Lee, J. Y. S., Song, Q., Zuo, Z., Muir, J. G., Chan, J. C. N., & Chow, E. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01336-4 · Cited by 11
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Alfaraidi, H., & Samaan, M. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072879 · Cited by 12
Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease
Greco, M., Munir, A., Musarò, D., Coppola, C., & Maffia, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1244022 · Cited by 10
Exploring the recent advancements and future prospects of personalized medicine in type 2 diabetes
Nameghi, S. M. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100193 · Cited by 16
Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance
Brīvība, M., Silamiķele, L., Kalniņa, I., Silamiķelis, I., Birzniece, L., Ansone, L., Jagare, L., Elbere, I., & Kloviņš, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232143 · Cited by 12
Treatment of type 2 diabetes in children: what are the specific considerations?
Grøndahl, M. F. G., Johannesen, J., Kristensen, K., & Knop, F. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1954160 · Cited by 12
Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes
Attaye, I., Witjes, J. J., Koopen, A. M., van der Vossen, E. W. J., Zwirs, D., Wortelboer, K., Collard, D., Kemper, E. M., Winkelmeijer, M., Holst, J. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110455 · Cited by 10
Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»
Dedov, I. I., Romantsova, T. I., & Shestakova, M. V. (2019) · Obesity and metabolism · doi:10.14341/omet10076 · Cited by 9
Intestinal TGR5-targeted carrier-drug conjugate improves glycemic control in mice and pigs
Zhang, Y., Huang, H., Wang, Y., Li, X., Hou, P., Yu, M., Zhang, Z., Guo, S., Liu, C., Zhang, Z., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado5177 · Cited by 8

Authors: Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S., Wattchow, D. A., Rehfeld, J. F., Holst, J. J., Keating, D. J., Vilsbøll, T., & Knop, F. K.
Affiliations: Gentofte Hospital (DK)
Flinders University (AU)
South Australian Health and Medical Research Institute (AU)
University of Copenhagen (DK)
Pfizer (United States) (US)
Discipline of Surgery, Flinders University, Adelaide, South Australia, Australia.
Corresponding author: Keating, Damien J.
Knop, Filip K.
ORCID: Sun, Emily W. L.
Young, Richard L.
Sonne, David P.
Hollington, Paul
Sposato, Luigi
Due, Steven
Wattchow, David A.
Rehfeld, Jens F.
Holst, Jens J.
Keating, Damien J.
Vilsbøll, Tina
Knop, Filip K.
Venue: JCI Insight
Publisher: American Society for Clinical Investigation
Published: 2018-12-06
Volume: 3
Issue: 23
ISSN: 2379-3708 (ISSN-L)
DOI: 10.1172/jci.insight.93936
PMC: PMC6328020
OpenAlex: W2903143648
Cited by: 173
References: 72
Citations by year: 2026: 15 · 2025: 22 · 2024: 28 · 2023: 23 · 2022: 18 · 2021: 30 · 2020: 22 · 2019: 15
FWCI: 13.32
Type: journal article
Language: en
Open access: gold
doi.org
Locations: JCI Insight (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders: AP Møller Fonden
the Novo Nordisk Foundation
Danish Medical Association
Australian Research Council (LP150100419)
National Health and Medical Research Council (APP1088737, APP1081182)
Pfizer (Emerging science grant)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: metformin, glucagon-like peptide-1, GLP-1 secretion, type 2 diabetes, AMPK, exendin-9-39, GLP-1 receptor antagonists, postprandial blood glucose, L cells, glucose-lowering mechanism
MeSH terms: Adult, Aged, Aged, 80 and over, Australia, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Metformin, Middle Aged, Postprandial Period, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks